Wall Street analyst estimates for Perspective Therapeutics, Inc. (CATX): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-09 | $-0.24 | ||
| 2026-08-10 | $-0.22 | $-0.25 | +12.4% |
| 2026-05-11 | $-0.25 | $-0.29 | +13.8% |
| 2026-03-16 | $-0.51 | $-0.37 | -37.8% |
| 2025-11-10 | $-0.35 | $-0.33 | -6.1% |
| 2025-08-13 | $-0.30 | $-0.30 | +0.0% |
| 2025-05-12 | $-0.25 | $-0.28 | +10.7% |
| 2025-03-26 | $-0.57 | $-0.26 | -119.2% |
Valuation Ratios
| Price / Book | 0.59 |
| EV / EBITDA | -2.37 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.8M | $5.9M | $7.3M | $9.7M | $10.1M | $10.8M | $5.4M | $1.4M | $1.5M | 0 |
| Cost of Revenue | $3.9M | $4.1M | $4.3M | $4.6M | $4.9M | $6.2M | $3.0M | 0 | $2.3M | 0 |
| Gross Profit | $838000 | $1.8M | $3.0M | $5.1M | $5.1M | $4.6M | $2.4M | $1.4M | -$852000 | 0 |
| Research & Development | $965000 | $1.7M | $1.5M | $1.1M | $1.4M | $2.6M | $1.8M | $21.3M | $39.3M | $84.2M |
| Selling, General & Admin | $6.2M | $6.8M | $6.9M | $7.5M | $7.1M | $9.4M | $9.4M | $21.1M | $26.6M | $30.2M |
| Operating Expenses | $7.1M | $8.6M | $8.3M | $8.6M | $8.6M | $12.0M | $11.5M | $42.4M | $65.9M | $113.6M |
| Operating Income | -$6.3M | -$6.7M | -$5.3M | -$3.5M | -$3.4M | -$7.4M | -$9.1M | -$40.9M | -$66.8M | -$113.6M |
| EBITDA | -$6.2M | -$6.7M | -$5.1M | -$3.5M | -$3.4M | -$7.1M | -$8.5M | -$40.0M | -$64.5M | -$100.8M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $84000 | $48000 | $376000 |
| Pre-tax Income | -$6.2M | -$6.7M | -$5.1M | -$3.4M | -$3.4M | -$7.3M | -$8.5M | -$40.1M | -$80.4M | -$104.4M |
| Income Tax | -$145000 | -$29000 | -$294000 | -$177000 | -$199000 | 0 | 0 | -$2.7M | -$2.1M | -$793000 |
| Net Income | -$6.2M | -$6.7M | -$4.8M | -$3.3M | -$3.2M | -$7.3M | -$10.8M | -$46.5M | -$79.3M | -$103.1M |
| EPS | $-0.11 | $-0.12 | $-0.07 | $-0.05 | $-0.06 | $-0.50 | $-0.60 | $-0.85 | $-1.23 | $-1.40 |
| EPS (Diluted) | $-0.11 | $-0.12 | $-0.07 | $-0.05 | $-0.06 | $-0.50 | $-0.60 | $-0.85 | $-1.23 | $-1.40 |
| Shares Outstanding (Diluted) | $55.0M | $55.2M | $67.0M | $67.6M | $54.9M | $14.2M | $14.2M | $54.9M | $64.4M | $73.8M |
Price
| Price | $2.88 |
| Market Cap | $328M |
| Exchange | AMEX |
| Country | US |
Related companies: AVR · ELMD · HSDT · IVVD · MXCT · NNOX · NYXH
Explore sector: Healthcare · Medical - Devices
More sections of CATX: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks